Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | SPIN1 | Q9Y657 | 2/20 | 0.54 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.54 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.54 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.52 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | WHR1 | P49842 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455285 | 1.00 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL3318391 | 0.99 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL3780652 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL17628123 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL17628121 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL13329878 | 0.82 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL13329880 | 0.82 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL9132869 | 0.81 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL14412487 | 0.81 | SPIN1 (0.74) | SMN1; SMN2ALDH1A1KDM4ESTAT6NPSR1 | |
| SCHEMBL28894133 | 0.80 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1NTSR1EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051290-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2025-02-13 | — | — | US | disclosed |
| WO-2023121429-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | 아주대학교산학협력단 | 2023-06-29 | — | — | WO | disclosed |
| WO-2019010180-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-01-10 | — | — | WO | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | SMN1; SMN2 1281/4885ALDH1A1 4857/4885KDM4E 1626/4885 |
| US-20250051290-A1 | NOVEL COMPOUND FOR IMPROVING SLEEP OR USE THEREOF | ADORA2A, HCRTR1, ADORA1 | SMN1; SMN2 2249/4885ALDH1A1 1796/4885KDM4E 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.